Definium Therapeutics Inc (DFTX) Proxy filing summary

Executive summary

• Annual General and Special Meeting scheduled for June 11, 2026, to be held virtually, allowing all shareholders equal participation regardless of location or equity ownership.

• Key business highlights include full enrollment in multiple Phase 3 clinical trials, a $259 million equity financing, and leadership team expansion in 2025–2026.

• The company rebranded to Definium Therapeutics, Inc. in January 2026 and began trading under the symbol DFTX.

Voting matters and shareholder proposals

• Shareholders will vote on: (1) election of seven directors to serve until the 2027 annual meeting, (2) appointment of KPMG as independent auditor until 2027, and (3) amendment to the 2025 Equity Incentive Plan to increase available shares by 5,000,000.

• Board recommends voting FOR all proposals.

• Shareholder proposals for the next annual meeting must be submitted by March 10, 2027 (BCBCA) or December 28, 2026 (SEC Rule 14a-8).

Board of directors and corporate governance

• Six of seven directors are independent; the CEO is not independent.

• Board committees (Audit, Compensation, Nominating and Corporate Governance) are fully independent.

• Board Chair and Vice Chair are independent; all directors are elected annually.

• Board and committee meeting attendance rates were 97.9% and 100%, respectively, in 2025.

• Board diversity: 29% women directors, 20% women executive officers.